McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

Original reporting
Published Oct 8, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
McKesson & CD&R Acquire Leading US Home-Infusion Platform — source image
Decision brief

The 30-second read

$MCKBullishHigh
01

Why it matters

The transaction provides McKesson with a foothold in outpatient infusion, expanding its specialty pharma logistics network.

02

Market read

Large M&A deal in healthcare distribution sector with immediate price impact potential for both acquirer and target.

03

What to watch

Regulatory approvals and integration risks could delay expected synergies.

Relevance 9/10Novelty 9/10Timing: today

Background

McKesson partners with private‑equity firm CD&R to acquire Option Care Health, a leading U.S. home‑infusion platform.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

McKesson announced a $5.8bn acquisition of Option Care Health, taking a minority stake worth $1.4bn.

Expected impact

likely upward pressure as investors price in strategic expansion and cash deployment.

Evidence & confidence

Large‑scale M&A with clear strategic rationale; market typically rewards such announcements.

Market effects

Strengthens the home‑infusion and specialty pharma distribution sector, signaling consolidation and potential margin expansion.

U.S. healthcare distribution market may see increased M&A activity as firms seek scale.

Highlights growing importance of outpatient infusion services worldwide.

Counterpoint

Deal could strain McKesson's balance sheet and distract from core distribution business.

Key entities

  • McKesson

    U.S. healthcare distributor and acquirer.

  • Option Care Health

    Provider of outpatient infusion services.

  • Clayton, Dubilier & Rice

    Majority stakeholder in the transaction.

Related articles

$MCKLow

Built and Bred

McKesson (MCK) will invest $179M in a 330,000 sq. ft. regional distribution center in Moore, Oklahoma, creating 200+ jobs. The site's location, readiness, and regional coordination influenced the decision, according to the company.

$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.